Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Queensland Health
Johnson and Johnson
Accenture
Cerilliant
Federal Trade Commission
Covington
Moodys
McKesson

Generated: December 14, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR IRINOTECAN HYDROCHLORIDE

« Back to Dashboard

Clinical Trials for Irinotecan Hydrochloride

Trial ID Title Status Sponsor Phase Summary
NCT00001495 A Phase I Study of Irinotecan (CPT-11) Administered as a Prolonged Infusion in Adult Patients With Solid Tumors Completed National Cancer Institute (NCI) Phase 1 This study examines a 96 hour infusion schedule of irinotecan alternating with 72 hour drug-free intervals in patients with solid tumors in order to determine the maximum tolerated dose of this regimen.
NCT00002759 Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma Completed National Cancer Institute (NCI) Phase 1 Phase I trial to study the effectiveness of irinotecan plus cyclosporine and phenobarbital in treating patients who have solid tumors or lymphoma that is refractory to standard therapy. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Cyclosporine and phenobarbital may enhance the effectiveness of irinotecan.
NCT00002902 Irinotecan Plus ICI D1694 in Treating Patients With Advanced Solid Tumors Completed National Cancer Institute (NCI) Phase 1 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of irinotecan plus ICI D1694 in treating patients with advanced solid tumors.
NCT00002902 Irinotecan Plus ICI D1694 in Treating Patients With Advanced Solid Tumors Completed University of Pennsylvania Phase 1 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of irinotecan plus ICI D1694 in treating patients with advanced solid tumors.
NCT00002933 Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer Completed National Cancer Institute (NCI) Phase 2 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have metastatic or recurrent colorectal cancer.
NCT00002933 Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer Completed Case Comprehensive Cancer Center Phase 2 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have metastatic or recurrent colorectal cancer.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Irinotecan Hydrochloride

Condition Name

Condition Name for Irinotecan Hydrochloride
Intervention Trials
Colorectal Cancer 226
Metastatic Colorectal Cancer 110
Gastric Cancer 53
Colorectal Neoplasms 49
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Irinotecan Hydrochloride
Intervention Trials
Colorectal Neoplasms 472
Adenocarcinoma 110
Pancreatic Neoplasms 100
Stomach Neoplasms 88
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Irinotecan Hydrochloride

Trials by Country

Trials by Country for Irinotecan Hydrochloride
Location Trials
United States 3,470
Canada 221
Japan 140
Italy 133
China 123
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Irinotecan Hydrochloride
Location Trials
California 188
New York 182
Texas 137
Illinois 130
Ohio 123
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Irinotecan Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Irinotecan Hydrochloride
Clinical Trial Phase Trials
Phase 4 10
Phase 3 117
Phase 2/Phase 3 20
[disabled in preview] 966
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Irinotecan Hydrochloride
Clinical Trial Phase Trials
Completed 518
Recruiting 228
Unknown status 111
[disabled in preview] 249
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Irinotecan Hydrochloride

Sponsor Name

Sponsor Name for Irinotecan Hydrochloride
Sponsor Trials
National Cancer Institute (NCI) 258
Pfizer 46
Sanofi 31
[disabled in preview] 90
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Irinotecan Hydrochloride
Sponsor Trials
Other 1078
Industry 522
NIH 265
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Cerilliant
Chinese Patent Office
US Army
Cipla
Johnson and Johnson
Chubb
Queensland Health
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.